| HOME >> BIOLOGY >> TECHNOLOGY |
WEIFANG, Shandong, China, Aug. 4 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai Pharmaceutical" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it has retained Grayling Global to lead a strategic communications program ("the IR program") to shareholders, the investment community and financial media.
As the investor relations counsel for Shengtai Pharmaceutical, Grayling Global will help raise the investment community's awareness of the Company's performance through timely corporate updates, direct communications with fund managers, financial media placements and investor conference presentations. "We are pleased to have a global IR network and its senior counselors with long standing healthcare and industrial track records to help us raise our financial profile and ensure the full understanding of our business model and exciting growth prospects," said Mr. Qingtai Liu, Chief Executive Officer of Shengtai Pharmaceutical. "We need to increase our visibility and expand our relationships with U.S. investors. As we are becoming a bigger company and planning to move onto main exchange, we believe Grayling Global is best suited to guide this investor relations process."
Grayling Global, a subsidiary of Huntsworth PLC (LSE: HNT), is headquartered in London, with offices in New York, Brussels, Bangkok, Singapore, Madrid, Moscow, Tel Aviv, Hong Kong, Istanbul, Los Angeles, Sacramento, Dublin, Edinburgh, Cardiff, Bristol, and Birmingham. The firm has over 200 consultants, focusing on first-class delivery in public affairs, public relations, investor relations and events management.
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly-owned subsidiary
Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese
operating company of Weifang Shengtai Pharm
'/>"/>
| SOURCE Shengtai Pharmaceutical, Inc. Copyright©2008 PR Newswire. All rights reserved |